KRN7000

KRN 7000 is a potent synthetic α-galactosylceramide, which, in association with the antigen-presenting CD1d protein, activates NKT immune cells. As these cells have important roles in the rejection of malignant tumors and in the regulation of several autoimmune diseases, KRN 7000 has activity in many diseases, including cancer, lupus, diabetes, malaria, and tuberculosis.

White Solid

Galactosylceramides play an important roles in promoting the regulation of nerve cells, regulating protein kinase C activities and modulating the function of the hormone receptor. It has shown to have significant immunostimulatory and anti-umor activity in mice with liver metastasis of the Colon26 adenocarcinoma.

KRN 7000 is a potent synthetic α-galactosylceramide, which, in association with the antigen-presenting CD1d protein, activates NKT immune cells. As these cells have important roles in the rejection of malignant tumors and in the regulation of several autoimmune diseases, KRN 7000 has activity in many diseases, including cancer, lupus, diabetes, malaria, and tuberculosis.

ChEBI: A glycophytoceramide having an alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen.

-20°C

[1] H. J. J. VAN DER VLIET. Effects of α-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Vα24+ Vβ11+ T cells[J]. Immunology, 2001, 98 4: 557-563. DOI: 10.1046/j.1365-2567.1999.00920.x
[2] NOEMI A. SAAVEDRA-AVILA, AMY R. HOWELL*   A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells[J]. ACS Chemical Biology, 2024, 19 4: 926-937. DOI: 10.1021/acschembio.3c00736
[3] DEYING YANG . Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development[J]. Acta Pharmaceutica Sinica. B, 2022, 12 12: Pages 4432-4445. DOI: 10.1016/j.apsb.2022.05.028